Foley Hoag represented Ginkgo Bioworks on the deal. Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading platform for cell programming and biosecurity, announced its acquisition of StrideBio’s adeno-associated...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here